MPC-3100

• Description :

  MPC-3100 is an orally bioavailable, synthetic, second-generation small-molecule inhibitor of Hsp90 with potential antineoplastic activity[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H335

• Target :

  HSP

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/mpc-3100.html

• Purity :

  98.36

• Solubility :

  DMSO : 5.5 mg/mL (ultrasonic; warming)

• Smiles :

  NC1=C2C(N(CCC3CCN(C([C@@H](O)C)=O)CC3)C(SC4=C(Br)C=C(OCO5)C5=C4)=N2)=NC=N1

• Molecular Formula :

  C22H25BrN6O4S

• Molecular Weight :

  549.44

• Precautions :

  H315, H319, H335

• References & Citations :

  [1]Kim SH, et al. Discovery of (2S) -1-[4- (2-{6-amino-8-[ (6-bromo-1,3-benzodioxol-5-yl) sulfanyl]-9H-purin-9-yl}ethyl) piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a purine-based Hsp90 inhibitor. J Med Chem. 2012 Sep 13;55 (17) :7480-501.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [958025-66-6]